Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224094 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women
A Phase 4 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT00224094 is a Phase 4 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT00224094, a Phase 4 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study compares the effects of 12 weeks of treatment with transdermal versus oral estrogen therapy on testsoterone levels and thyroid tests in healthy, naturally menopausal women.
Interventions
- DRUG Premarin® (oral) vs. Alora® (transdermal)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2002-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224094
The ClinicalTrials.gov registry entry for NCT00224094 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Premarin® (oral) vs. Alora® (transdermal) is the first listed.
NCT00224094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224094 about?
NCT00224094 is a clinical study titled "A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women". This study compares the effects of 12 weeks of treatment with transdermal versus oral estrogen therapy on testsoterone levels and thyroid tests in healthy, naturally menopausal women.
What is the current status of trial NCT00224094?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2002-01.
What interventions are being tested in trial NCT00224094?
The interventions under investigation include: Premarin® (oral) vs. Alora® (transdermal) (DRUG).
Who is sponsoring clinical trial NCT00224094?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.